97 related articles for article (PubMed ID: 21964185)
1. Discovery of pyridine-2-ones as novel class of multidrug resistance (MDR) modulators: first structure-activity relationships.
Krawczyk S; Otto M; Otto A; Coburger C; Krug M; Seifert M; Tell V; Molnár J; Hilgeroth A
Bioorg Med Chem; 2011 Nov; 19(21):6309-15. PubMed ID: 21964185
[TBL] [Abstract][Full Text] [Related]
2. Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
Baumert C; Günthel M; Krawczyk S; Hemmer M; Wersig T; Langner A; Molnár J; Lage H; Hilgeroth A
Bioorg Med Chem; 2013 Jan; 21(1):166-77. PubMed ID: 23199479
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.
Coburger C; Lage H; Molnár J; Langner A; Hilgeroth A
J Pharm Pharmacol; 2010 Dec; 62(12):1704-10. PubMed ID: 21054396
[TBL] [Abstract][Full Text] [Related]
4. First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators.
Krug M; Voigt B; Baumert C; Lüpken R; Molnár J; Hilgeroth A
Eur J Med Chem; 2010 Jun; 45(6):2683-8. PubMed ID: 20207048
[TBL] [Abstract][Full Text] [Related]
5. Lathyrane diterpenes from Euphorbia lathyris as modulators of multidrug resistance and their crystal structures.
Jiao W; Dong W; Li Z; Deng M; Lu R
Bioorg Med Chem; 2009 Jul; 17(13):4786-92. PubMed ID: 19443229
[TBL] [Abstract][Full Text] [Related]
6. Jatrophane diterpenes as modulators of multidrug resistance. Advances of structure-activity relationships and discovery of the potent lead pepluanin A.
Corea G; Fattorusso E; Lanzotti V; Motti R; Simon PN; Dumontet C; Di Pietro A
J Med Chem; 2004 Feb; 47(4):988-92. PubMed ID: 14761200
[TBL] [Abstract][Full Text] [Related]
7. New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance.
Schmidt M; Ungvári J; Glöde J; Dobner B; Langner A
Bioorg Med Chem; 2007 Mar; 15(6):2283-97. PubMed ID: 17276076
[TBL] [Abstract][Full Text] [Related]
8. Enhancing macrocyclic diterpenes as multidrug-resistance reversers: structure-activity studies on jolkinol D derivatives.
Reis M; Ferreira RJ; Santos MM; dos Santos DJ; Molnár J; Ferreira MJ
J Med Chem; 2013 Feb; 56(3):748-60. PubMed ID: 23336337
[TBL] [Abstract][Full Text] [Related]
9. 3'-O, 4'-O-aromatic acyl substituted 7,8-pyranocoumarins: a new class of P-glycoprotein modulators.
Shen X; Chen G; Zhu G; Cai J; Wang L; Hu Y; Fong WF
J Pharm Pharmacol; 2012 Jan; 64(1):90-100. PubMed ID: 22150676
[TBL] [Abstract][Full Text] [Related]
10. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Gopinath VS; Thimmaiah P; Thimmaiah KN
Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Boumendjel A; Di Pietro A; Dumontet C; Barron D
Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
[TBL] [Abstract][Full Text] [Related]
12. Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells.
Paterna A; Kincses A; Spengler G; Mulhovo S; Molnár J; Ferreira MU
Eur J Med Chem; 2017 Mar; 128():247-257. PubMed ID: 28189906
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors.
Voigt B; Coburger C; Monár J; Hilgeroth A
Bioorg Med Chem; 2007 Aug; 15(15):5110-3. PubMed ID: 17533131
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
16. Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes.
Perestelo NR; Sánchez-Cañete MP; Gamarro F; Jiménez IA; Castanys S; Bazzocchi IL
Eur J Med Chem; 2011 Oct; 46(10):4915-23. PubMed ID: 21856049
[TBL] [Abstract][Full Text] [Related]
17. Prolongation of pentoxifylline aliphatic side chain positively affects the reversal of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells.
Docolomanský P; Fialová I; Barancík M; Rybár A; Breier A
Gen Physiol Biophys; 2005 Dec; 24(4):461-6. PubMed ID: 16474189
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of pyrazole-based hybrid molecules: search for potent multidrug resistance modulators.
Singh P; Paul K; Holzer W
Bioorg Med Chem; 2006 Jul; 14(14):5061-71. PubMed ID: 16554161
[TBL] [Abstract][Full Text] [Related]
19. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents.
Boumendjel A; Baubichon-Cortay H; Trompier D; Perrotton T; Di Pietro A
Med Res Rev; 2005 Jul; 25(4):453-72. PubMed ID: 15834856
[TBL] [Abstract][Full Text] [Related]
20. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
